Jonathan Sackner-Bernstein (born 27 January 1961) is an American physician. He has published more than 80 scientific articles, which have been cited more than 4,000 times. His research has ranged from cardiac care to the efficacy of drugs. His research led to increased scrutiny of

Nesiritide Nesiritide, sold under the brand name Natrecor, is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate cardiovascular fluid homeostas ...

, a widely marketed drug, which led to its decline in its use.

Education

Sackner-Bernstein graduated from the University of Pennsylvania's

Moore School of Electrical Engineering The Moore School of Electrical Engineering at the University of Pennsylvania came into existence as a result of an endowment from Alfred Fitler Moore on June 4, 1923. It was granted to Penn's School of Electrical Engineering, located in the Towne ...

in 1983 (BSEE),. He completed his MD from

Jefferson Medical College Thomas Jefferson University is a private research university in Philadelphia, Pennsylvania. Established in its earliest form in 1824, the university officially combined with Philadelphia University in 2017. To signify its heritage, the univer ...

, during which he moonlit writing code. He completed a residency in internal medicine and subsequently cardiology at Mount Sinai Hospital in New York. In addition, Sackner-Bernstein completed a research fellowship in heart failure under Milton Packer at Mount Sinai.

Academic, clinical and research experience

Sackner-Bernstein joined the

Columbia University Columbia University (also known as Columbia, and officially as Columbia University in the City of New York) is a private research university in New York City. Established in 1754 as King's College on the grounds of Trinity Church in Manhatt ...

faculty in 1993 in the Division of Circulatory Physiology, where he established its clinical research program. He accumulated a large experience with the beta-blocker

carvedilol Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure (CHF), and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is gen ...

prior to the application by its developer (

GlaxoSmithKline GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. GSK is the ten ...

) to the US

Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respon ...

(FDA). His most cited research focused on whether the newly marketed heart failure drug

nesiritide Nesiritide, sold under the brand name Natrecor, is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate cardiovascular fluid homeostas ...

(hr-BNP, Natrecor) was safe and effective, with a call for large-scale clinical trials prior to widespread use. While nesiritide was projected to generate $1 billion in sales in 2006, these studies triggered controversy that eventually led to markedly lower use by physicians. Other frequently cited articles include work on Carvedilol and cardiac hypertrophy. He is also the author of a book on heart disease, ''Before It Happens To You.''

US government projects

Sackner-Bernstein joined the

FDA The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food s ...

in 2008 as Associate Center Director, leading Post Market Operations as well as Technology and Innovation programs. As the Center's first Associate Center Director for Technology and Innovation, Sackner-Bernstein launched the Innovation Initiative in 2011, which subsequently led to the Early Feasibility Program and laid the foundation for the Breakthrough Device Program. He also helped establish a formal relationship between FDA and

DARPA The Defense Advanced Research Projects Agency (DARPA) is a research and development agency of the United States Department of Defense responsible for the development of emerging technologies for use by the military. Originally known as the Adv ...

(Defense Advanced Research Projects Agency), then serving as architect for the initial Entrepreneurs-in-Residence Program. sponsored by the

White House Office of Science and Technology Policy White is the lightest color and is achromatic (having no hue). It is the color of objects such as snow, chalk, and milk, and is the opposite of black. White objects fully reflect and scatter all the visible wavelengths of light. White on ...

(OSTP)

Commercial projects

From late 2018 to mid 2019, Sackner-Bernstein served as Chief Medical Officer and EVP, Clinical and Regulatory Affairs for ROX Medical.

References

External links

Personal website, jsbmd.com

“Science 2.0” 1972 Dolphins vs 2007 Patriots
30 January 2008
TED Profile and Link to TEDx Talk
{{DEFAULTSORT:Sackner-Bernstein, Jonathan American cardiologists 1961 births Living people Thomas Jefferson University alumni Jefferson Medical College alumni 21st-century American inventors